MARK Substrate
Need Assistance?
  • US & Canada:
    +
  • UK: +

MARK Substrate

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

MARK Substrate is a MARK substrate peptide.

Category
Others
Catalog number
BAT-009283
CAS number
847991-34-8
Molecular Formula
C60H108N18O21
Molecular Weight
1417.61
Synonyms
L-Lysine, L-asparaginyl-L-valyl-L-lysyl-L-seryl-L-lysyl-L-isoleucylglycyl-L-seryl-L-threonyl-L-α-glutamyl-L-asparaginyl-L-leucyl-; Asn-Val-Lys-Ser-Lys-Ile-Gly-Ser-Thr-Glu-Asn-Leu-Lys
Appearance
White Lyophilized Powder
Purity
≥95%
Sequence
NVKSKIGSTENLK
Storage
Store at -20°C
Solubility
Soluble in Water
1. Proteasome Structure and Assembly
Lauren Budenholzer, Chin Leng Cheng, Yanjie Li, Mark Hochstrasser J Mol Biol. 2017 Nov 10;429(22):3500-3524. doi: 10.1016/j.jmb.2017.05.027. Epub 2017 Jun 3.
The eukaryotic 26S proteasome is a large multisubunit complex that degrades the majority of proteins in the cell under normal conditions. The 26S proteasome can be divided into two subcomplexes: the 19S regulatory particle and the 20S core particle. Most substrates are first covalently modified by ubiquitin, which then directs them to the proteasome. The function of the regulatory particle is to recognize, unfold, deubiquitylate, and translocate substrates into the core particle, which contains the proteolytic sites of the proteasome. Given the abundance and subunit complexity of the proteasome, the assembly of this ~2.5MDa complex must be carefully orchestrated to ensure its correct formation. In recent years, significant progress has been made in the understanding of proteasome assembly, structure, and function. Technical advances in cryo-electron microscopy have resulted in a series of atomic cryo-electron microscopy structures of both human and yeast 26S proteasomes. These structures have illuminated new intricacies and dynamics of the proteasome. In this review, we focus on the mechanisms of proteasome assembly, particularly in light of recent structural information.
2. N6-methyladenosine marks primary microRNAs for processing
Claudio R Alarcón, Hyeseung Lee, Hani Goodarzi, Nils Halberg, Sohail F Tavazoie Nature. 2015 Mar 26;519(7544):482-5. doi: 10.1038/nature14281. Epub 2015 Mar 18.
The first step in the biogenesis of microRNAs is the processing of primary microRNAs (pri-miRNAs) by the microprocessor complex, composed of the RNA-binding protein DGCR8 and the type III RNase DROSHA. This initial event requires recognition of the junction between the stem and the flanking single-stranded RNA of the pri-miRNA hairpin by DGCR8 followed by recruitment of DROSHA, which cleaves the RNA duplex to yield the pre-miRNA product. While the mechanisms underlying pri-miRNA processing have been determined, the mechanism by which DGCR8 recognizes and binds pri-miRNAs, as opposed to other secondary structures present in transcripts, is not understood. Here we find in mammalian cells that methyltransferase-like 3 (METTL3) methylates pri-miRNAs, marking them for recognition and processing by DGCR8. Consistent with this, METTL3 depletion reduced the binding of DGCR8 to pri-miRNAs and resulted in the global reduction of mature miRNAs and concomitant accumulation of unprocessed pri-miRNAs. In vitro processing reactions confirmed the sufficiency of the N(6)-methyladenosine (m(6)A) mark in promoting pri-miRNA processing. Finally, gain-of-function experiments revealed that METTL3 is sufficient to enhance miRNA maturation in a global and non-cell-type-specific manner. Our findings reveal that the m(6)A mark acts as a key post-transcriptional modification that promotes the initiation of miRNA biogenesis.
3. How to evaluate premature ventricular beats in the athlete: critical review and proposal of a diagnostic algorithm
Domenico Corrado, Jonathan A Drezner, Flavio D'Ascenzi, Alessandro Zorzi Br J Sports Med. 2020 Oct;54(19):1142-1148. doi: 10.1136/bjsports-2018-100529. Epub 2019 Sep 3.
Although premature ventricular beats (PVBs) in young people and athletes are usually benign, they may rarely mark underlying heart disease and risk of sudden cardiac death during sport. This review addresses the prevalence, clinical meaning and diagnostic/prognostic assessment of PVBs in the athlete. The article focuses on the characteristics of PVBs, such as the morphological pattern of the ectopic QRS and the response to exercise, which accurately stratify risk. We propose an algorithm to help the sport and exercise physician manage the athlete with PVBs. We also address (1) which athletes need more indepth investigation, including cardiac MRI to exclude an underlying pathological myocardial substrate, and (2) which athletes can remain eligible to competitive sports and who needs to be excluded.
Online Inquiry
Verification code
Inquiry Basket